Major pharmaceutical companies are struggling to meet double-digit growth objectives with a growing pressure to increase R&D productivity and find replacement blockbuster drugs. M&A is an effective way of increasing R&D capabilities, building the product portfolio and also cutting operating costs. This article considers certain hurdles in Big Pharma mergers and suggestions to overcome those hurdles.